Prostate Cancer Genomic Classifier VL

The Molecular Biology of Prostate Cancer - Christopher Barbieri

Details
Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....

An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt...

Details
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk non-met...

Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross

Details
In this discussion, Alicia Morgans and Ashley Ross discuss men in the adjuvant setting with the highest risk of prostate cancer metastasis by genomic stratification. They focus their discussion on Decipher molecular testing after prostatectomy and the Phase III ERADICATE study. The ERADICATE trial was presented at this year's ASCO meeting. Biographies: Ashley Ross, MD, Ph.D., Associate Professor,...

Rationale for the Use of Decipher RP Genomic Classifier to Inform Treatment - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic prog...

The Use of the Decipher Biopsy Test Prior to Prostatectomy - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss the Decipher Biopsy genomic risk assessment test and its use prior to prostatectomy. Dr Ross shares how and why he has integrated this genomic risk stratification test into his clinical practice. The use of Decipher allows patients to be risk stratified based upon the genomics of the tumor tissue and physicians can use the results to determine the course of t...

Decipher Biopsy and Decipher for Prostatectomy in Clinical Practice- Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss Decipher testing, both Decipher Biopsy and Decipher for prostatectomy specimens, and how to integrate these tests into standard clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to strati...

Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray

Details
Jason Hafron and Katie Murray join Ashley Ross in a conversation on the treatment of unfavorable intermediate-risk prostate cancer and the value of the genomic classifier useful in guiding treatment considerations. Biographies: Jason Hafron, MD, Associate Professor of Urology, The William Beaumont School of Medicine, Oakland University, Director of Robotic Surgery, Beaumont Hospital Royal Oak, Aub...

The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan

Details
Daniel Spratt and Amar Kishan discuss a Lancet Oncology publication, on behalf of the MARCAP Consortium, titled "Androgen Deprivation Therapy Use and Duration with Definitive Radiotherapy for Localised Prostate Cancer: An Individual Patient Data Meta-Analysis." Led by Dr. Kishan, this individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various andro...

The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal

Details
Alicia Morgans sits down with Brandon Mahal to explore the complexities of using salvage systemic therapy alongside salvage radiation therapy for post-prostatectomy patients. Dr. Mahal outlines the current conundrum: whether to administer Androgen Deprivation Therapy (ADT) and for how long, especially for men with high PSAs post-surgery. He references multiple randomized trials that offer conflict...

The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra

Details
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor and A...